A Review of the Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Nonhematologic Malignancies DOI Creative Commons

Defne Cigdem Koc,

Ion Bogdan Mănescu, Măriuca Mănescu

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(18), P. 2057 - 2057

Published: Sept. 16, 2024

Biomarkers are crucial in cancer diagnostics, prognosis, and surveillance. Extensive research has been dedicated to identifying biomarkers that broadly applicable across multiple types can be easily obtained from routine investigations such as blood cell counts. One biomarker, the neutrophil-to-lymphocyte ratio (NLR), established a prognostic marker cancer. However, due dynamic nature of diagnosis treatment, periodic updates necessary keep abreast vast amount published data. In this review, we searched PubMed database analyzed synthesized recent literature (2018–February 2024) on role NLR predicting clinical outcomes nonhematologic malignancies. The search was conducted using database. We included total 88 studies, encompassing 28,050 human subjects, categorized findings into four major groups: gastrointestinal cancer, cancers urinary tract reproductive system, lung breast Our analysis confirms is reliable indicator discuss specific characteristics, limitations, exceptions associated with its use. review concludes concise Q&A section, presenting most relevant take-home messages response five key practical questions topic.

Language: Английский

Trial watch: dexmedetomidine in cancer therapy DOI Creative Commons
Killian Carnet Le Provost, Oliver Kepp, Guido Kroemer

et al.

OncoImmunology, Journal Year: 2024, Volume and Issue: 13(1)

Published: March 11, 2024

Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that widely used in intensive and anesthetic care for its sedative anxiolytic properties. DEX has the capacity to alleviate inflammatory pain while limiting immunosuppressive glucocorticoid stress during major surgery, thus harboring therapeutic benefits oncological procedures. Recently, molecular mechanisms of DEX-mediated anticancer effects have been partially deciphered. Together with additional preclinical data, these mechanistic insights support hypothesis DEX-induced are mediated via stimulation adaptive anti-tumor immune responses. Similarly, published clinical trials including ancillary studies described an immunostimulatory role perioperative period cancer surgery. The impact on long-term patient survival remains elusive. Nevertheless, immunostimulation offers interesting option onco-anesthesia. Our present review comprehensively summarizes data from as well ongoing distinct focus overcoming (tumor microenvironment (TME)-imposed) therapy resistance. objective this update guide clinicians their choice toward onco-anesthetic agents improve disease outcome.

Language: Английский

Citations

9
In vitro and in vivo efficacy studies of an engineered endolysin targeting gram-negative pathogens DOI Creative Commons

Hyewon Hong,

Jaeyeon Jang,

Young Deuk Kim

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 140463 - 140463

Published: Jan. 1, 2025

Language: Английский

Citations

0
Trial watch: local anesthetics in cancer therapy DOI Creative Commons
Killian Carnet Le Provost,

Oliver Kepp,

Guido Kroemer

et al.

OncoImmunology, Journal Year: 2024, Volume and Issue: 13(1)

Published: March 17, 2024

Preclinical evidence indicates potent antitumor properties of local anesthetics. Numerous underlying mechanisms explaining such anticancer effects have been identified, suggesting direct cytotoxic as well indirect immunemediated that together reduce the proliferative, invasive and migratory potential malignant cells. Although some retrospective correlative studies support these findings, prospective randomized controlled trials not yet fully confirmed antineoplastic activity anesthetics, likely due to intricate methodology required for mitigating confounding factors. This trial watch aims at compiling all published preclinical clinical research, along with completed ongoing trials, explore

Language: Английский

Citations

2
pH-responsive nanogels with enhanced antioxidant and antitumor activities on drug delivery and smart drug release DOI
Bing Ma, Qing Li,

Yingqi Mi

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 257, P. 128590 - 128590

Published: Dec. 4, 2023

Language: Английский

Citations

6
A Review of the Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Nonhematologic Malignancies DOI Creative Commons

Defne Cigdem Koc,

Ion Bogdan Mănescu, Măriuca Mănescu

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(18), P. 2057 - 2057

Published: Sept. 16, 2024

Biomarkers are crucial in cancer diagnostics, prognosis, and surveillance. Extensive research has been dedicated to identifying biomarkers that broadly applicable across multiple types can be easily obtained from routine investigations such as blood cell counts. One biomarker, the neutrophil-to-lymphocyte ratio (NLR), established a prognostic marker cancer. However, due dynamic nature of diagnosis treatment, periodic updates necessary keep abreast vast amount published data. In this review, we searched PubMed database analyzed synthesized recent literature (2018–February 2024) on role NLR predicting clinical outcomes nonhematologic malignancies. The search was conducted using database. We included total 88 studies, encompassing 28,050 human subjects, categorized findings into four major groups: gastrointestinal cancer, cancers urinary tract reproductive system, lung breast Our analysis confirms is reliable indicator discuss specific characteristics, limitations, exceptions associated with its use. review concludes concise Q&A section, presenting most relevant take-home messages response five key practical questions topic.

Language: Английский

Citations

1